ACE inhibitors are well-established for limiting morbidity and mortality after MI, particularly in patients with LV dysfunction, heart failure, or both. To test the hypothesis that an ...

Angiotensin-converting enzyme (ACE) inhibitors are the mainstay of therapy for patients with systemic sclerosis in scleroderma renal crisis, however mortality remains high even in the post-ACE ...

ACE inhibitor use delays development of renal involvement in patients with systemic lupus erythematosus (SLE). In a study of 378 SLE patients, 80 (21%) were ACE inhibitor users and 298 (79%) were not.

Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a ...

Thus, ACE inhibitors appear not to mediate angioedema through an allergic or idiosyncratic reaction; rather, they seem to facilitate angioedema in predisposed individuals. Despite the aforementioned ...

For immediate post-MI patients, sacubitril/valsartan (Entresto; Novartis) does not significantly decrease the risk of heart failure (HF) or CV death compared with an ACE inhibitor, the PARADISE-MI ...

Cardiovascular illnesses, such as high blood pressure and heart problems, are often treated with angiotensin-converting enzyme (ACE) inhibitors. The ACE inhibitors lower blood pressure by relaxing ...

OBJECTIVES: Many patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) experience a delay in treatment or fail to initiate treatment with guideline-recommended angiotensin-converting ...

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are antihypertensive medicines used to treat high blood pressure. While the enzyme inhibitors work by reducing the level of ...

Rupert Payne does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...